alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › assay

assay

14 studies tagged assay, dated 2017-07-12 to 2025-07-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Equivalence of Plasma and Serum for Clinical Measurement of p-tau217: Comparative Analyses of Four Blood-Based Assays 2025-07-01
  2. Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay 2025-05-01
  3. A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer's disease 2025-04-01

Studies

14 studies carry this tag.

Date range

2017 to 2025

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 4
  • Alzheimer's research & therapy 2
  • Journal of Alzheimer's disease : JAD 2
  • Clinical chemistry and laboratory medicine 1
  • Diagnostics (Basel, Switzerland) 1

9 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Equivalence of Plasma and Serum for Clinical Measurement of p-tau217: Comparative Analyses of Four Blood-Based Assays

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of neurochemistry 2025-07-01 Biomarkers

    Phosphorylated tau (p-tau) 217 is a promising blood biomarker for Alzheimer's disease (AD).

  2. Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-05-01 Biomarkers

    We underline the potential of next-generation biomarker identification tools to detect novel proteomic features that also incorporate established biomarkers.

  3. A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-04-01 Biomarkers

    LMW-specific p-tau assays could be more useful in the diagnostic workup of AD, especially in population-based communities where conditions causing peripheral neuropathy are frequent.

  4. PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Diagnostics (Basel, Switzerland) 2024-08-10 Biomarkers

    Alzheimer's disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern.

  5. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's research & therapy 2024-03-07 Biomarkers

    Our results show that the measurement of p-Tau181 in plasma has great potential as a non-invasive prognostic screening tool for implementation in a clinical setting.

  6. A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-01-06 Biomarkers

    This study demonstrated the utility of a blood-based, multi-pathway biomarker assay for early screening and staging of AD, providing insights for patient stratification and precision medicine.

  7. CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Clinical chemistry and laboratory medicine 2023-09-04 Biomarkers

    Differences observed in technical and diagnostic performance of the two assays may depend on matrix-specific amyloid processing, suggesting that further studies should be carried to standardize amyloid ratio measurement in plasma.

  8. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline

    ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Alzheimer's research & therapy 2023-01-05 Biomarkers

    This study suggests that plasma Aβ42/Aβ40, as determined by this MS-based assay, has potential value as an accurate and cost-effective tool to identify individuals in the earliest stages of AD, supporting its implementation in clinical trials, preventative strategies and clinical practice.

  9. Reactive Astrocytes Contribute to Alzheimer's Disease-Related Neurotoxicity and Synaptotoxicity in a Neuron-Astrocyte Co-culture Assay

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in cellular neuroscience 2022-01-21 Biomarkers

    Pathogenesis of presymptomatic disease stages remains elusive, although studies suggest that the early structural and functional alterations likely occur at neuronal dendritic spines.

  10. Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer's disease: a systematic review and meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Translational neurodegeneration 2021-03-12 Biomarkers

    A lack of convenient and reliable biomarkers for diagnosis and prognosis is a common challenge for neurodegenerative diseases such as Alzheimer's disease (AD).

  11. Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease - A cross-validation study

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Nanomedicine : nanotechnology, biology, and medicine 2020-03-25 Biomarkers

    Blood-based biomarker assays of plasma β-amyloid (Aβ) and tau have the advantages of cost-effective and less invasive for the diagnosis of Alzheimer's disease (AD).

  12. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01 Biomarkers

    In this sample, the high-throughput blood Aβ assay was not able to distinguish well between AD patients and controls.

  13. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01 Biomarkers

    This study confirms strong concordance between CSF biomarkers and PET Aβ-amyloid status is independent of immunoassay platform, supporting their utility as biomarkers in clinical practice for the diagnosis of AD and for participant enrichment in clinical trials.

  14. Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2017-07-12 Biomarkers

    Assay drift may reduce statistical power or even confound analyses.

All topic tags with their study counts